Trial Profile

An open‐label, multicenter study to evlauate the effect of Renal Impairment on the Pharmacokinetics of ALKS 3831

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olanzapine/samidorphan (Primary)
Indications Bipolar disorders; Psychotic disorders; Schizophrenia
Focus Pharmacokinetics

Most Recent Events

06 May 2019 New trial record
16 Mar 2019 Results evaluating the effected of Renal Impairment (RI) on the PK parameters of ALKS 3831 are presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com